CAMP4 Therapeutics Secures $50M Initial Financing With Potential For Additional $50M To Fund SYNGAP1 Phase 1/2 Clinical Trial
Benzinga Newsdesk 1 year ago
News
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investorsFinancing to provide $50 million in upfront proceeds with the potential for up to an additional $50 million of proceeds
Oversubscribed Financing led by Coastlands Capital with participation from new and existing investors
Financing to provide $50 million in upfront proceeds with the potential for up to an additional $50 million of proceeds to fund the Phase 1/2 clinical trial in patients with SYNGAP1-related disorders, expected to initiate as early as 2H 2026
Doug Williams, Ph.D., to become Board Chair, and Dan Tardiff, Ph.D., elevated to Chief Scientific Officer